First Clinical Data Presented with IMGN853, ImmunoGen, Inc.’s Potential New Therapy for Ovarian and Other Cancers

Published: Jun 03, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload (TAP) ADC technology, today announced the presentation of the first clinical data with the Company’s IMGN853 product candidate. The data are from the ongoing dose-finding portion of a Phase I clinical assessment of the compound, which is a potential treatment for many ovarian, endometrial, and non-small cell lung cancers, as well as other FRa-overexpressing cancers.

Help employers find you! Check out all the jobs and post your resume.

Back to news